- Moderna stock jumps sharply on Wednesday, up over 8%.
- News of a Merck option boosts the stock.
- News around covid is also seen to boost Moderna's potential.
Moderna (MRNA) was one of the hot stocks of the covid era before eventually winding down as it appeared we had finally overcome the scourge of covid. Perhaps not so fast as the WHO says Europe is facing a new wave but hopefully not as bad as previous ones. Moderna's stock price has slid as covid itself slinks off into the background. The stock is down 45% year to date and nearly 58% in the past 12 months.
Moderna stock news
We have already outlined the strong cash position Moderna is in after massive revenues from sales of its covid drugs. In our article Three dividend stocks that look interesting for the long run: BHP, MRNA, BTI, I cheekily included Moderna despite it not yet paying a dividend. With so much cash, however, it will come under pressure to return some to shareholders either via dividends or buybacks. Moderna already has alluded to this in its earnings release.
Source: Refinitiv
Moderna stock spiked 8% on Wednesday. Merck (MRK) has exercised its option to jointly develop and commercialise Moderna's new cancer vaccine. Merck will pay Moderna $250 million for the option, and the two companies will then split costs and profits equally. Also of note as mentioned above is the potential for Moderna's covid vaccine revenues to extend. The WHO said it looks like another wave of covid in Europe has begun and encouraged people to get vaccinated. Moderna and Pfizer covid vaccines were also approved for kids as young as five years old by the FDA. These are the updated shots that target the new strains of covid.
Moderna stock forecast
This zone that I have highlighted from $110 to $120 has again acted as a strong support point on the long-term chart. Moderna will announce earnings on November 2, and data from the work with Merck is expected in Q4, so there are news catalysts due. We need to keep an eye on the speed of the move. The stochastic looks overbought, but as yet we have no confirmation signals from the Relative Strength Index (RSI).
Moderna (MRNA) stock, daily
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD holds on to intraday gains after upbeat US data
EUR/USD remains in positive ground on Friday, as profit-taking hit the US Dollar ahead of the weekend. Still, Powell's hawkish shift and upbeat United States data keeps the Greenback on the bullish path.
GBP/USD pressured near weekly lows
GBP/USD failed to retain UK data-inspired gains and trades near its weekly low of 1.2629 heading into the weekend. The US Dollar resumes its advance after correcting extreme overbought conditions against major rivals.
Gold stabilizes after bouncing off 100-day moving average
Gold trades little changed on Friday, holding steady in the $2,560s after making a slight recovery from the two-month lows reached on the previous day. A stronger US Dollar continues to put pressure on Gold since it is mainly priced and traded in the US currency.
Bitcoin to 100k or pullback to 78k?
Bitcoin and Ethereum showed a modest recovery on Friday following Thursday's downturn, yet momentum indicators suggest continuing the decline as signs of bull exhaustion emerge. Ripple is approaching a key resistance level, with a potential rejection likely leading to a decline ahead.
Week ahead: Preliminary November PMIs to catch the market’s attention
With the dust from the US elections slowly settling down, the week is about to reach its end and we have a look at what next week’s calendar has in store for the markets. On the monetary front, a number of policymakers from various central banks are scheduled to speak.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.